BiomX Inc.

BiomX Inc. (Nasdaq: PHGE) reached the public markets through a merger with Chardan Healthcare Acquisitions Corp., a blank-check company sponsored by affiliates of Chardan Capital Markets. The SPAC filed its S-1 registration statement in November 2018 and completed its initial public offering in early 2019, targeting the life sciences and biotechnology sector. BiomX, an Israeli-founded clinical-stage biopharmaceutical company, develops phage-based therapies designed to selectively target and eliminate disease-causing bacteria, with a focus on chronic inflammatory and infectious diseases. The business combination closed in October 2019, after which the combined company began trading under the PHGE ticker on the NYSE American. Sign up for full data, filing history, and sponsor intelligence on BiomX and thousands of other SPAC transactions at SpacDesk.